Skip to main content
Premium Trial:

Request an Annual Quote

SAIC-Frederick, Fluidigm Collaborate to Decode Epstein-Barr Virus Genome

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SAIC-Frederick and Fluidigm today announced a collaboration to decode the entire genome of the Epstein-Barr virus.

Under the partnership, SAIC-Frederick researchers at the Core Genotyping Facility will use the Fluidigm Access Array system to target and amplify the genome of EBV DNA virus. After targeting and amplification, the DNA can be processed through next-generation sequencing equipment "that decodes the DNA's chemical sequence in sufficient depth to illuminate key genetic variations," SAIC said in a statement.

Some of the sequences have already been decoded and can be further studied, it added.

SAIC-Frederick is the prime contractor for the National Cancer Institute's R&D facility in Frederick, Md. The collaboration with Fluidigm is part of the NCI Advanced Technology Partnerships Initiative.

Herpes-related EBV is one of the most common viruses in humans. Though the virus establishes viruses that are typically asymptomatic, in rare cases it can lead to diseases, including some cancers. Understanding the virus at the genetic level should shed light on why some patients become ill but others don't, which in turn could lead to better treatments, SAIC said.

Terms of the agreement were not disclosed.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.